Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Adrenal Gland Pheochromocytoma”

14 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 14 of 14 results

Not applicableAvailableNCT01590680
What this trial is testing

Expanded Access Protocol Using 131I-MIBG

Who this might be right for
NeuroblastomaPheochromocytomaParaganglioma
Jubilant DraxImage Inc.
Not applicableStudy completedNCT01850888
What this trial is testing

MIBG for Refractory Neuroblastoma and Pheochromocytoma

Who this might be right for
Relapsed NeuroblastomaMetastatic Pheochromocytoma
Masonic Cancer Center, University of Minnesota 15
Testing effectiveness (Phase 2)Active Not RecruitingNCT04284774
What this trial is testing

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Who this might be right for
Malignant Solid NeoplasmRecurrent Adrenal Gland PheochromocytomaRecurrent Ectomesenchymoma+38 more
National Cancer Institute (NCI) 5
Early research (Phase 1)Looking for participantsNCT04119024
What this trial is testing

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Who this might be right for
Metastatic Malignant Solid NeoplasmMetastatic MelanomaPathologic Stage IIIC Cutaneous Melanoma AJCC v8+14 more
Anusha Kalbasi 18
Not applicableApproved For MarketingNCT02961491
What this trial is testing

Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Who this might be right for
PheochromocytomaParaganglioma
Molecular Insight Pharmaceuticals, Inc.
Not applicableAvailableNCT03015844
What this trial is testing

A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma

Who this might be right for
NeuroblastomaPheochromocytoma
Northwell Health
Not applicableNo Longer AvailableNCT03649438
What this trial is testing

131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma

Who this might be right for
Relapsed NeuroblastomaMetastatic Pheochromocytoma
University of Texas Southwestern Medical Center
Early research (Phase 1)Study completedNCT00049023
What this trial is testing

Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

Who this might be right for
Brain and Central Nervous System TumorsGastrointestinal Carcinoid TumorIslet Cell Tumor+4 more
O'Dorisio, M S 27
Testing effectiveness (Phase 2)UnknownNCT00874614
What this trial is testing

A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Who this might be right for
PheochromocytomaParaganglioma
Molecular Insight Pharmaceuticals, Inc. 74
Not applicableNo Longer AvailableNCT01838187
What this trial is testing

Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

Who this might be right for
NeuroblastomaPheochromocytomaParaganglioma
Children's Hospital Medical Center, Cincinnati
Testing effectiveness (Phase 2)Looking for participantsNCT00107289
What this trial is testing

Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

Who this might be right for
NeuroblastomaPheochromocytoma
Memorial Sloan Kettering Cancer Center 200
Not applicableWithdrawnNCT04770831
What this trial is testing

Patients Who Receive 131 I-MIBG

Who this might be right for
Brain and Nervous System
Wake Forest University Health Sciences
Early research (Phase 1)Ended earlyNCT00002947
What this trial is testing

Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer

Who this might be right for
Brain and Central Nervous System TumorsChildhood Langerhans Cell HistiocytosisGastrointestinal Carcinoid Tumor+9 more
Yale University 35
Not applicableAvailableNCT01163383
What this trial is testing

131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol

Who this might be right for
NeuroblastomaChildhood Metastatic Pheochromocytoma
John Maris